TrialAssure’s ANONYMIZE has been selected by the European Medicines Agency as its official tool to anonymise clinical trial documents for public release under EMA transparency measures such as Policy 0070. The platform pairs AI‑assisted detection with human review to protect participant privacy while preserving scientific value. The decision followed a structured vendor evaluation in 2025 and comes as the EDPB’s Guidelines 1/2026 reaffirm that pseudonymised data remains personal data under the GDPR.
EMA Names TrialAssure ANONYMIZE Official Tool For Clinical Trial Data Anonymisation
Global differences in data protection can make it difficult for sponsors to conduct research. Credit: dee karen / Shutterstock.com
TrialAssure’s ANONYMIZE platform has been chosen by the European Medicines Agency (EMA) as the agency’s official solution for anonymising clinical trial documents. The Netherlands‑based company’s system will be used to redact dossiers and other clinical materials submitted by market authorisation holders so that participant identities and privacy are protected when documents are published under EMA transparency initiatives such as Policy 0070.
What the Platform Does
ANONYMIZE is designed to handle sensitive information across a broad array of clinical documents, datasets and medical images. The platform combines AI‑assisted detection with expert human review to identify and remove or mask personally identifiable information while seeking to preserve the scientific utility and context of the underlying data.
Selection Process
The EMA’s choice followed a structured vendor evaluation and market research process. TrialAssure participated in that selection process in 2025 as the agency sought scalable, auditable and compliant solutions to meet growing transparency and data‑protection requirements.
Prasad Koppolu, TrialAssure Chief Operating Officer: "We are proud to have been selected following the EMA’s evaluation process. Anonymisation should be a core capability that scales, stands up to scrutiny, is auditable and preserves the value of the data — and that is exactly what we have built."
Regulatory Context
On 15 April 2026 the European Data Protection Board (EDPB) adopted Guidelines 1/2026 on processing personal data for scientific research purposes, reiterating that pseudonymised data is still considered personal data under the General Data Protection Regulation (GDPR). That guidance clarifies obligations for controllers and processors handling research data across different fields and technologies.
Implications For Global Trials And AI Use
Privacy rules differ by jurisdiction — for example, U.S. clinical trial privacy is governed principally by HIPAA, the Common Rule and FDA regulations — and those geographic differences complicate planning and running multi‑country studies. Sponsors remain responsible for complying with applicable data‑protection laws, which can make harmonised data collection across countries challenging, especially for smaller biotech firms.
As artificial intelligence is adopted more widely in clinical research, regulators including the EMA and FDA are increasing scrutiny and issuing guidance to ensure patient privacy is maintained when AI tools are used for data processing and anonymisation.
Bottom Line
The EMA’s selection of TrialAssure ANONYMIZE signals a push toward standardized, auditable approaches to publishing clinical information while balancing transparency and patient privacy in a complex regulatory landscape.
Help us improve.
